House Committee requests documents on EpiPen price hikes from Mylan CEO

U.S Reps. Jason Chaffetz (R-Utah) and Elijah Cummings (D-Md.) of the House Committee on Oversight and Government Reform on Monday sent a letter to Mylan CEO Heather Bresch requesting documents and communications regarding the EpiPen price hike, according to Reuters.

Reps. Chaffetz and Cummings, the committee's chairman and a ranking member, respectively, requested documents containing information on revenue from sales of EpiPens, a life-saving severe allergy treatment, since 2007. The representatives are also seeking information on manufacturing costs and reimbursement Mylan receives from Medicare and Medicaid.

Mylan said Monday it plans to release a generic version of EpiPen for $300, half of the price of the brand name product, in response to mounting pressure and criticism from the public, policymakers and medical organizations.

More articles on supply chain:
FDA approves new flu vaccine
The rise of the unbranded drug ad: 5 things to know
FDA fast tracks experimental drug to treat Parkinson's

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.